Darinaparsin · Darvias

Small molecule

Also known as ZIO-101

Approvedregulatory verdict

Evidence outlook

Approved: Relapsed or refractory peripheral T-cell lymphoma (DARVIAS Injection 135 mg) (JP)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Weak signal

Also approved (1)
JP
  • Relapsed or refractory peripheral T-cell lymphoma (DARVIAS Injection 135 mg)
Product first approved 2022biospace.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Peripheral T-Cell Lymphoma
Other / comorbidity
NCT00421213 · Alaunos Therapeutics
2006-12-29 – 2009-06-30 · Hematologic Neoplasms, Bone Marrow Neoplasms, Non-Hodgkin's Lymphoma
What this study did
NCT00423644 · Alaunos Therapeutics
2007-01 – 2008-12-21 · Multiple Myeloma
What this study did
NCT00423306 · Alaunos Therapeutics
2007-05-01 – 2008-08-09 · Hepatocellular Carcinoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT00303199 · Alaunos Therapeutics
2006-01 – 2007-08 · Multiple Myeloma
What this study did
Phase 1 (9)
Peripheral T-Cell Lymphoma
NCT01435863 · Solasia Pharma K.K.
2011-09 – 2015-07 · Peripheral T-cell Lymphoma
What this study did
NCT01689220 · Solasia Pharma K.K.
2012-09 – 2014-09 · Peripheral T-cell Lymphoma
What this study did
Other / comorbidity
NCT01139346 · Alaunos Therapeutics
2010-06 – 2012-04 · Advanced Solid Tumors
What this study did
NCT01139359 · Alaunos Therapeutics
2010-06 – 2011-06 · Lymphoma
What this study did
NCT00591422 · Alaunos Therapeutics
2007-08 – 2011-03-10 · Advanced Cancer
What this study did
NCT00592163 · Alaunos Therapeutics
2007-12 – 2010-01-04 · Advanced Solid Tumors, Lymphomas
What this study did
NCT00591396 · Alaunos Therapeutics
2005-07 – 2008-07 · Solid Tumors
What this study did
NCT00509782 · M.D. Anderson Cancer Center
2005-05 – 2008-04 · Solid Tumors
What this study did

Competitive landscape

This drug's own stage for Peripheral T-Cell Lymphoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Darinaparsin (Darvias): this drugPhase 2Small moleculeapoptosis via reactive oxygen species (ROS) generation and mitochondrial disruptionWeak signalNo reviewed efficacy summary in this indication
BelinostatApprovedSmall moleculeHistone Deacetylase Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
SoquelitinibPhase 3Small moleculeITKnot yet gradedNo reviewed efficacy summary in this indication
Valemetostat Tosylate (Ezharmia)Phase 2Small moleculeEZH1/2not yet gradedNo reviewed efficacy summary in this indication
ZeprumetostatPhase 2Small moleculeEZH1/2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.